MMP26 Antibody
- Known as:
- MMP26 Antibody
- Catalog number:
- XW-7753
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- MMP26 Antibody
Related genes to: MMP26 Antibody
- Gene:
- MMP26 NIH gene
- Name:
- matrix metallopeptidase 26
- Previous symbol:
- -
- Synonyms:
- endometase, MGC126590, MGC126592
- Chromosome:
- 11p15.4
- Locus Type:
- gene with protein product
- Date approved:
- 2000-12-13
- Date modifiied:
- 2016-10-05
Related products to: MMP26 Antibody
Related articles to: MMP26 Antibody
- : Detection of cervical lesions is crucial for effective prevention and treatment. Therefore, the search for new diagnostic markers is extremely important. This study aimed to evaluate the concentration and diagnostic utility of selected matrix metalloproteinases (MMPs) as novel biomarkers. : The study group consisted of 320 participants: 160 patients with cervical cancer (CC), 100 patients with cervical dysplasia (CD), and 60 healthy controls (HC). MMPs were determined by an ELISA (Enzyme-Linked Immunosorbent Assay), and CA 125 and SCC-Ag by a CMIA (chemiluminescent microparticle immunoassay). : Our study revealed significantly higher concentrations of MMP-7 and MMP-10 in the CC and CD groups compared to healthy controls. Interestingly, concentrations of these two parameters increased with the advancement of the disease. In the case of MMP-3, the highest concentrations were observed in the CD group, moderate concentrations in the group with diagnosed CC, and the lowest in the group of healthy women. Notably, the concentration of this parameter in the CC group decreased with increasing disease advancement. In the case of MMP-26, the highest concentrations, which increased with advancement, were observed in CC, moderate concentrations in HC, and the lowest in the group of women with CD. The highest diagnostic usefulness among all the parameters was shown for MMP-7 (sensitivity (SE): 96%; specificity (SP): 94.14%; positive predictive value (PPV): 92.26%; negative predictive value (NPV): 85.46%; area under the curve (AUC): 0.9878) and MMP-10 (SE: 90.25%; SP: 80.05%; PPV: 92.15%; NPV: 88.45%; AUC: 0.9404). : All parameters presented significant differences between the concentrations obtained in the CC group and the CD group, which may indicate their usefulness not only in the diagnosis of cervical cancer, but also in the possible differentiation between benign and malignant lesions. - Source: PubMed
Publication date: 2025/11/27
Gacuta EwaŁawicki MichałGrabowska HannaŁawicki PawełKulesza MonikaKicman AleksandraZajkowska MonikaLaudański PiotrŁawicki Sławomir - Endometrioid ovarian cancer (EnOC) is a late-diagnosed gynecological cancer with limited diagnostic methods that, when detected at an early stage, has a good prognosis. This study is the first to evaluate the plasma concentrations and diagnostic utility of selected metalloproteinases as new biomarkers for EnOC. : The study group consisted of 50 newly diagnosed, untreated patients with EnOC; the control group consisted of 25 patients with endometrial cysts, 25 patients with serous cysts, and 50 healthy women. Selected matrilysins and stromelysins were determined by means of immunoenzymatic assay (ELISA) and routine markers (CA125 and HE4) using the chemiluminescence (CMIA) method. Higher levels of MMP-7, MMP-10, MMP-11, and MMP-26 were found in patients with EnOC when compared to healthy women. Concentrations of MMP-7, MMP-10, and MMP-11 were higher in women with EnOC when compared to benign lesions (BL). The highest SE (98.55%), NPV (95.41%), ACC (57.58%), and AUC (0.9658) values were obtained for MMP-7. High values of diagnostic parameters were also obtained for MMP-11 and MMP-26. These results suggest the usefulness of MMP-7, MMP-26, and MMP-11 in the diagnosis of EnOC as new biomarkers in this pilot study. - Source: PubMed
Publication date: 2025/09/02
Gacuta EwaKicman AleksandraŁawicki PawełŁawicki MichałKulesza MonikaMalinowski PawełChlabicz MarcinZajkowska MonikaŁawicki Sławomir - To explore the application value of joint detection of serum neutrophil-to-lymphocyte ratio (NLR), prostate-specific antigen (PSA) and MMP26 in differentiating prostate cancer (PCa) from benign prostatic hyperplasia (BPH). - Source: PubMed
Wang Yi-JinLi QiangFu Guang-Bo - Ovarian cancer (OC) has an extremely unfavourable prognosis. This is due to its asymptomatic course and lack of screening tests. Therefore, new methods are needed to diagnose OC. The aim of this study was to evaluate the concentrations and diagnostic utility of selected matrilysins and stromelysins in the diagnosis of OC in comparison with the classical markers CA125 and HE4. The study group included 100 patients with serous OC, 70 with serous cysts (BL), and 50 healthy women (HW). Selected MMPs were determined by ELISA, routine markers by CMIA. Ovarian cancer patients have elevated concentrations of MMP-7, MMP-26, MMP-10 as well as CA125 and HE4 in the total group and subgroups (stage I + II, and III + IV). The highest values of diagnostic parameters-SP, SE, NPV, PPV, and ACC, as compared to CA125 and HE4, were observed for MMP-7. Performing ROC analyses showed that the highest AUC values were observed for MMP-7, CA125, and HE4, in the whole group of patients and divided into stages I and II according to FIGO. Performing ROC analyses for groups III and IV according to FIGO was associated with an increase in AUC for the MMPs studied. Of the MMPs tested, MMP-7, MMP-26, and MMP-10 have the highest potential in diagnostics of serous ovarian cancer patients. - Source: PubMed
Publication date: 2025/06/13
Ewa GacutaŁawicki PawełGrabowska HannaŁawicki MichałKulesza MonikaKicman AleksandraMalinowski PawełŁawicki Sławomir - Metalloproteinases (MMPs) play a significant role in cancer pathogenesis. We investigated the levels of MMP-7, MMP-26, MMP-3, and MMP-10 in comparison with the levels of a tumor marker (CA125) in the plasma of postmenopausal patients in early stages of endometrial cancer (EC) compared with control groups: patients with benign lesions () and healthy controls. Plasma MMP levels were determined by ELISA and CA125 by CMIA methods. The study showed that plasma MMP-7 levels were significantly higher in EC patients compared to both control groups, whereas MMP-3 and MMP-26 levels were significantly higher in EC patients than in healthy women. MMP-7 showed the highest diagnostic sensitivity (SE), specificity (SP), positive (PPV) and negative predictive value (NPV), and diagnostic power (AUC) compared to other MMPs or CA125 in EC patients overall and patients with stage I and II EC. A combined analysis showed higher SE, NPV, and AUC levels in total EC patients and stage I and II EC patients-with the highest values for the combination MMP-7+CA125 (96%, 92%, 95%; 95%, 96%, and 98%; 0.9420, 0.9158, and 0.9693, respectively) or MMP-26 with CA125 (86%, 86%, and 86%; 59%, 73%, 73%; 0.8219, 0.8086, and 0.8353, respectively). The results suggest the usefulness of MMPs, especially MMP-7 and MMP-26, in combined panels with CA125 in diagnosing EC patients. - Source: PubMed
Publication date: 2025/04/18
Gacuta EwaŁawicki MichałKulesza MonikaŁawicki PawełKicman AleksandraŁubińska EmiliaŁawicki Sławomir